Evidence map›Paper›PMID 41639727›Full record

Observational studyItalian journal of pediatrics2026

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study.

Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, Piemonitorab Study Group

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elisa Funiciello *Pediatric Onco-Hematology Department and Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy. elisa.funiciello@unito.it.ORCID http://orcid.org/0000-0001-7042-881X
Alessia Spadavecchia *Department of Public Health and Pediatrics, University of Turin, Turin, Italy.
Celeste CagnazzoPediatric Onco-Hematology Department and Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Lorenza FerraraPiedmont Region, Health and Welfare Department, Turin, Italy.
Bartolomeo GriglioPiedmont Region, Health and Welfare Department, Turin, Italy.
Antonino SottilePiedmont Region, Health and Welfare Department, Turin, Italy.
Paola BerchiallaDepartment of Biological and Clinical Sciences, University of Turin, Turin, Italy.
Franca FagioliPediatric Onco-Hematology Department and Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Piemonitorab Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease. Immunization with the monoclonal antibody nirsevimab has shown efficacy in preventing RSV infection and reducing disease severity. This study aimed to evaluate the real-world effectiveness of a universal nirsevimab prophylaxis program against RSV-related LRTIs in children in the Piedmont region, Italy.

methodsA prospective, multicenter, observational study was conducted in the Piedmont Region (Italy). The primary endpoints were to assess nirsevimab immunization coverage among eligible infants and the number of RSV-related emergency department (ED) visits and hospitalizations during the 2024–2025 RSV season (October 1, 2024 to March 31, 2025). Secondary endpoints included the occurrence of adverse events following nirsevimab administration and the frequency of severe RSV-related outcomes, including intensive care unit (ICU) admission, need for respiratory support, and antibiotic therapy. The outcomes observed during the 2024–2025 season were compared with those from the 2022–2023 and 2023–2024 seasons.

resultsDuring the study period, nirsevimab was administered to 71.5% of the eligible infants. According to individual-level analyses restricted to the at-risk population, nirsevimab-immunized children had a significantly lower risk of RSV-related ED visits (RR 0.14, 95% CI 0.11–0.18), hospitalization (RR 0.15, 95% CI 0.11–0.20), respiratory support (RR 0.14, 95% CI 0.09–0.19), and antibiotic therapy (RR 0.08, 95% CI 0.02–0.28) than nonimmunized children did. The estimated nirsevimab effectiveness exceeded 80% for RSV-related ED visits, hospitalization, and respiratory support. Compared with the two previous RSV seasons, the 2024–2025 season presented a notable decrease in RSV-related healthcare utilization.

conclusionUniversal nirsevimab prophylaxis is associated with a substantial reduction in medically attended RSV-related LRTIs among infants experiencing their first RSV season, including fewer ED visits and a lower frequency of severe disease requiring hospitalizations, respiratory support, and antibiotic use.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus InfectionsFemaleHospitalizationHumansInfantItalyMaleProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedAntiviral AgentsLow respiratory tract infectionsNewbornsNirsevimabProphylaxisRSV

Identifiers

PMID41639727
PMCPMC12964948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.